Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary

References

• Konangi S, Raviteja MN, Gupta N. Comparison of global regulatory approvals for biosimilar products. Int J PharmTech Res. 2013;5(3):924–935.
   Google Scholar
• Kerpel-Fronius S. [Biological drugs price support clinical pharmacology perspective]. IME. 2010;9(8): 52–58. Hungarian.
   Google Scholar
• Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in central and Eastern European countries. Front Pharmacol. 2017 Jun;8(8):288.
   PubMed Web of Science ®Google Scholar
• Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? PharmacoEconomics. 2016;34:609–616.
   PubMed Web of Science ®Google Scholar
• Jakovljevic MB, Vukovic M, Fontanesi J. Life expectancy and health expenditure evolution in Eastern Europe-DiD and DEA analysis. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):537–546.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Kaló Z. Fair global drug pricing. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):581–583.
   PubMed Web of Science ®Google Scholar
• Haustein R, de Millas C, Höer A, et al. Saving money in the European healthcare systems with biosimilars. GaBI J. 2012;1(3–4):120–126.
   Google Scholar
• Inotai A, Nagy B, Kaló Z. [Biosimilar products and health policy-making evidence-based Central and Eastern Europe]. Med Training Rev Panel. 2012;19(12): 69–73. Hungarian.
   Google Scholar
• Hornyak L, Nagy Z, Talos Z, et al. [The experience of biosimilar medicines price competition in Hungary]. Acta Pharm Hung. 2014;84(2):83–87. Hungarian.
   PubMedGoogle Scholar
• Répásy B, Endrei D, Zemplényi A, et al. [Generic price competition in the drug traffic and the impact of social assistance outflows in Hungary]. Acta Pharm Hung. 2015;85(3):83–88. Hungarian.
   PubMedGoogle Scholar
• Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–312.
   PubMed Web of Science ®Google Scholar
• Gulacsi L, Pentek M, Rencz F, et al. Biosimilars for the management of inflammatory bowel diseases: economic considerations. Curr Med Chem. 2017 Apr 6. DOI:10.2174/0929867324666170406112304
   PubMed Web of Science ®Google Scholar
• Boncz I, Sebestyen A. Financial deficits in the health services of the UK and Hungary. Lancet. 2006;368(9539):917–918.
   PubMed Web of Science ®Google Scholar
• Baji P, Boncz I, Jenei G. Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries. Soc Economy. 2012;34(2):221–240.
   Google Scholar
• Kaló Z, Boncz I, Inotai A. Implications of economic crisis on health care decision-making in Hungary: an opportunity to change? JHPOR. 2012;1:20–26.
   Google Scholar
• Boncz I, Kaló Z, Mohamed I, et al. Further steps in the development of pharmacoeconomics, outcomes research, and health technology assessment in Central and Eastern Europe, Western Asia, and Africa. Value Health Reg. 2013;2(2):169–170.
   Google Scholar
• Boncz I, Donkáné Verebes É, Oberfrank F. [The impact of the Hungarian drug economic act for pharmacies between 2007-2010]. Acta Pharm Hung. 2013;83(1): 28–32. Hungarian.
   PubMedGoogle Scholar
• Boncz I, Nagy J, Sebestyen A, et al. Financing of health care services in Hungary. Eur J Health Econ. 2004;5(3):252–258.
   PubMedGoogle Scholar
• Gaal P, Szigeti S, Csere M, et al. Hungary health system review. Health Syst Transit. 2011;13(5):1–266.
   PubMedGoogle Scholar
• Endrei D, Molics B, Ágoston I. Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value Health. 2014;17(4):487–489.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Rencz F, Péntek M, et al. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2015;15:1–7.
   PubMed Web of Science ®Google Scholar
• 32/2004. (IV. 26.) [ESzCsM aspects of the regulation and the inclusion or change in the support of the Committee for Proprietary Medicinal Products and the inclusion of the dietary foods for particular nutritional uses of social insurance subsidies]. Hungarian.
   Google Scholar
• Kaló Z, Bodrogi J, Boncz I, et al. Capacity building for HTA implementation in middle-income countries: the case of Hungary. Value Health Reg. 2013;2(2):264–266.
   Google Scholar
• Gulacsi L, Boncz I, Drummond M. Issues for countries considering introducing the „fourth hurdle”: the case of Hungary. Int J Technol Assess Health Care. 2004;20(3):337–341.
   PubMed Web of Science ®Google Scholar
• Boncz I, Evetovits T, Dózsa C, et al. The Hungarian care managing organization pilot program value health regional. 2015;7:27–33.
   Google Scholar
• Boncz I, Dozsa C, Kalo Z, et al. Development of health economics in Hungary between 1990-2006. Eur J Health Econ. 2006;7(S1):4–6.
   Google Scholar
• Gulacsi L, Vas G, Pinter I, et al. Colorectal cancer screening policy in Hungary. Int J Technol Assess Health Care. 2009;25(1):109–110.
   PubMed Web of Science ®Google Scholar
• Boncz I, Nagy J, Kőrösi L, et al. The effect of the introduction of visit fee on the number of patient-visits to outpatient care departments in Hungary. Value Health. 2008;11(6):A368–A369.
   Web of Science ®Google Scholar
• Pentek M, Zrubka Z, Gulacsi L. The economic impact of biosimilars on chronic immune-mediated inflammatory diseases. Curr Pharm Des. 2017;23(44):6770–6778.
   PubMed Web of Science ®Google Scholar
• Gulácsi L, Brodszky V, Péntek M, et al. History of health technology assessment in Hungary. Int J Technol Assess Health Care. 2009;25(S1):120–126.
   PubMed Web of Science ®Google Scholar
• Buzás Z. [Allow biosimilar products on the European Medicines Agency for the system]. Med Training Rev. 2012;19(10): 73–79. Hungarian.
   Google Scholar
• Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw. 2011;9(8):934–942.
   PubMed Web of Science ®Google Scholar
• Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologist needs to know – a position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008;23(12):3731–3737.
   PubMed Web of Science ®Google Scholar
• Sun D, Andayani TM, Altyar A, et al. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European union G5 countries: a simulation study. Clin Ther. 2015;37(4):842–857.
   PubMed Web of Science ®Google Scholar
• Gulácsi L, Brodszky V, Baji P, et al. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European Countries. Adv Ther. 2017;34(5):1128–1144.
   PubMed Web of Science ®Google Scholar
• Kim J, An Hong J, Kudrin A. 5 year budget impact analysis of CT-P13 (infliximab) for the treatment of Crohn’s disease in UK, Italy and France. J Crohns Colitis. 2015;9(Suppl 1):S144.
   Google Scholar
• Grewal S, Ramsey S, Balu S, et al. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):447–454. Epub 2018 May 18.
   PubMed Web of Science ®Google Scholar